 Antibodies, Neutralizing
"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 2 | 2 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 4 | 5 | | 2012 | 6 | 2 | 8 | | 2013 | 2 | 3 | 5 | | 2014 | 3 | 2 | 5 | | 2015 | 2 | 4 | 6 | | 2016 | 1 | 4 | 5 | | 2017 | 7 | 6 | 13 | | 2018 | 7 | 6 | 13 | | 2019 | 2 | 4 | 6 | | 2020 | 7 | 7 | 14 | | 2021 | 15 | 17 | 32 | | 2022 | 2 | 19 | 21 | | 2023 | 0 | 6 | 6 | | 2024 | 1 | 4 | 5 | | 2025 | 4 | 6 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, Travisano KA, Filsinger Interrante MV, Bruun TUJ, Rezek V, Wilder B, Palomares M, Seaman MS, Kitchen SG, Bloom JD, Kim PS. A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning. Nat Commun. 2025 May 18; 16(1):4617.
-
Janoff EN, Shih MC, Donskey C, Belitskaya-Levy I, Brau N, Rodriguez-Barradas MC, Chan E, Zimmerman P, Miller EK, Vaughan LB, Daniel Markley J, Goldberg AM, Sriram P, Anzueto A, Uyeda L, Zehm L, Wills A, Hutchinson C, Jones L, Peterson D, Ringer RJ, Dumont L, Gleason T, Bonomo RA, Curtis JL, Brown ST. Impact of High-Titer Convalescent Plasma on Clinical and Virologic Outcomes Among Veterans Hospitalized With SARS-CoV-2 Infection: VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1). J Med Virol. 2025 May; 97(5):e70349.
-
Feist WN, Luna SE, Ben-Efraim K, Filsinger Interrante MV, Amorin A, Johnston NM, Bruun TUJ, Utz A, Ghanim HY, Lesch BJ, McLaughlin TM, Dudek AM, Porteus MH. Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies. Nat Commun. 2025 Apr 01; 16(1):3103.
-
Stumpf MM, Brunetti T, Davenport BJ, McCarthy MK, Morrison TE. Deep mutationally scanned CHIKV E3/E2 virus library maps viral amino acid preferences and predicts viral escape mutants of neutralizing CHIKV antibodies. J Virol. 2025 Apr 15; 99(4):e0008125.
-
Rudy MJ, Wilson CJ, Hinckley B, Baker DC, Royal JM, Hoke MP, Brennan MB, Vogt MR, Clarke P, Tyler KL. EV68-228-N monoclonal antibody treatment halts progression of paralysis in a mouse model of EV-D68 induced acute flaccid myelitis. mBio. 2025 Apr 09; 16(4):e0390624.
-
Guthmiller JJ, Yu-Ling Lan L, Li L, Fu Y, Nelson SA, Henry C, Stamper CT, Utset HA, Freyn AW, Han J, Stovicek O, Wang J, Zheng NY, Huang M, Dugan HL, Tepora ME, Zhu X, Chen YQ, Palm AE, Shaw DG, Loganathan M, Francis BF, Sun J, Chervin J, Troxell C, Meade P, Leung NHL, Valkenburg SA, Cobey S, Cowling BJ, Wilson IA, Garc?a-Sastre A, Nachbagauer R, Ward AB, Coughlan L, Krammer F, Wilson PC. Long-lasting B cell convergence to distinct broadly reactive epitopes following vaccination with chimeric influenza virus hemagglutinins. Immunity. 2025 Apr 08; 58(4):980-996.e7.
-
Cunningham CK, McFarland EJ, Muresan P, Capparelli EV, Perlowski C, Johnston B, Bone F, Purdue L, Yin DE, Moye J, Spiegel HML, Majji S, Theron GB, Mujuru HA, Purswani M, Alvarez G, Deville JG, Chambers C, Brown E, Harding PA, Tobin NH, Low K, Gama L. Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1. J Pediatric Infect Dis Soc. 2025 Feb 06; 14(2).
-
Mourad A, Grandits GA, Siegel LK, Engen N, Barkauskas C, Eriobu N, Jain MK, Jensen TO, Ginde A, Higgs E, Knox DB, Kitonsa J, Kim K, Malin JJ, Rapti V, Price DA, Mena Lora AJ, Mathews G, Mylonakis E, Murray TA, Sandkovsky U, Paredes R, Ramachandruni S, Reilly C, Vock D, Williamson JC, Young BE, Self WH, Lundgren J, Holland TL. Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial. Clin Microbiol Infect. 2025 Jun; 31(6):1053-1060.
-
Lin TH, Lee CD, Fern?ndez-Quintero ML, Ferguson JA, Han J, Zhu X, Yu W, Guthmiller JJ, Krammer F, Wilson PC, Ward AB, Wilson IA. Structurally convergent antibodies derived from different vaccine strategies target the influenza virus HA anchor epitope with a subset of VH3 and VK3 genes. Nat Commun. 2025 Feb 02; 16(1):1268.
-
Kirby MB, Petersen BM, Faris JG, Kells SP, Sprenger KG, Whitehead TA. Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive. Proc Natl Acad Sci U S A. 2025 Jan 28; 122(4):e2412787122.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|